DaoudE., BodorG.Ca 125 concentration in malignant and non-malignant disease.Clin Chem1991; 37: 1968–74
2.
ZeimetA.G., OffnerF.A., MarthC.Modulation of Ca 125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells.Anticancer-Res1997; 17: 3129–31
3.
DiBaiseJ.K., DonovanJ.P.Markedly elevated Ca 125 in hepatic cirrhosis.J Clin Gastroenterol1999; 28: 159–61
4.
ZuckermanE., LanirA., SaboF.Ca 125 as a marker for detection and quantitation of ascites in liver cirrhosis [Abstract].Hepatology1995; 22: A163
5.
CollazosJ., GenollaJ., RuibalA.Ca 125 serum level in patients with nonneoplastic liver diseases. A clinical and laboratory study.Scand J Clin Lab Invest1992; 52: 201–6
6.
MeyerT., RustinG.J.Role of tumour markers in monitoring epithelial ovarian cancer.Br J Cancer2000; 82: 1535–8
7.
JacobsI.J., OramD., FairbanksJ., TurnerJ., FrostC., GrudzinskasJ.G.A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.Br J Obstet Gynaecol1990; 97: 922–9
8.
JacobsI.J., SkatesS.J., MacDonaldN.Screening for ovarian cancer: a pilot randomised controlled trial.Lancet1999; 353: 1207–10
9.
PiccartM.J., BertelsenK., JamesK.Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.J Natl Cancer Inst2000; 92: 699–708
10.
MenonU., TalaatA., JeyerajahA., RosenthalA.N.Ultrasound assessment of ovarian cancer risk in postmenopausal women with Ca 125 elevation.Br J Cancer1999; 80: 1644–7
